Medulloblastoma is a heterogeneous embryonal tumor of the cerebellum comprised of four
distinct molecular subgroups that differ in their developmental origins, genomic landscapes …

Purpose Patients with MYC-amplified Group 3 medulloblastoma (MB)(subtype II) show poor
progression-free survival rates. Class I histone deacetylase inhibitors (HDACi) are highly …

Simple Summary In this review, we summarize reported molecular mechanisms underlying
tumor progression and relapse of medulloblastoma, one of the most frequent malignant …

Background Preclinical models like cancer cell lines and patient‐derived xenografts (PDXs)
are vital for studying disease mechanisms and evaluating treatment options. It is essential …

Group 3 medulloblastoma is one of the most aggressive types of childhood brain tumors.
Roughly 30% of cases carry genetic alterations in MYC, SMARCA4, or both genes …

Background Seizures are prevalent in glioma patients, especially in those with low-grade
gliomas. The interaction between gliomas and epilepsy involves complex biological …

Human umbilical cord mesenchymal stem cells (hUMSCs) belong to a multipotent stem cell
population. Transplantation of icariin (ICA)-treated hUMSCs have better tissue repairing …

The formation of metastases during cancer is now considered to be induced by migrating
metastatic stem cells (MetSCs) in preexisting niches or niches induced by MetSCs or tumor …

Background Medulloblastoma (MB) is the most common high-grade pediatric brain tumor,
comprised of 4 main molecular subgroups—sonic-hedgehog (SHH), Wnt, Group 3, and …

Brain tumors are one of the most concerning disorders of modern times, yet comprehensive
knowledge on their symptoms, risk factors, diagnosis, treatment, and post-treatment in …